help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
This version published online on September 5, 2006
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2006-0023
A more recent version of this article appeared on November 1, 2006
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
91/11/4232    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rosenbloom, A. L.
Right arrow Articles by Guevara-Aguirre, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rosenbloom, A. L.
Right arrow Articles by Guevara-Aguirre, J.

Submitted on January 5, 2006
Accepted on August 1, 2006

Controversy in Clinical Endocrinology: Reclassification of IGF-1 Production and Action Disorders

Arlan L. Rosenbloom* and Jaime Guevara-Aguirre

Arlan L. Rosenbloom, Division of Endocrinology, Department of Pediatrics, University of Florida College of Medicine, Gainesville Florida; Jaime Guevara-Aguirre, Instituto Endocrinologia, Metabolismo y Reproduccion, Quito Ecuador

Context: The need for the least ambiguous terminology for disorders affecting insulin-like growth factor-I (IGF-I) production and action has become necessary with identification of defects at various steps in the GH-IGF-I axis and the promotion of new indications for and modalities of growth therapy. No generally agreed-upon or consensus-derived classification exists.

Objective: To designate all disorders affecting IGF-I production and action by their discrete location, as is already done with the defects in pituitary differentiation factors, avoiding imprecise and ambiguous terminology.

Conclusions: We propose a pragmatic classification that is a precise listing of specific disorders sequentially following the GH-IGF-I axis, using their accepted designations, and the abolition of nonspecific or ambiguous terminology. This concept permits ready insertion of new discoveries.




This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
P. F. Collett-Solberg, M. Misra, and on behalf of the Drug and Therapeutics Committee o
The Role of Recombinant Human Insulin-Like Growth Factor-I in Treating Children with Short Stature
J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 10 - 18.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. M. Domene, P. A. Scaglia, A. Lteif, F. H. Mahmud, S. Kirmani, J. Frystyk, P. Bedecarras, M. Gutierrez, and H. G. Jasper
Phenotypic Effects of Null and Haploinsufficiency of Acid-Labile Subunit in a Family with Two Novel IGFALS Gene Mutations
J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4444 - 4450.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. L. Levitsky
Defining the Role of IGF-I Therapy for Short Children
J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 813 - 814.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2006 by The Endocrine Society